Retractable Technologies
Makes retractable syringes, safety needles, and blood-collection devices.
Something off on this page? Send us feedback.
Profile
Sells retractable syringes, safety needles, and blood-collection devices primarily through distributors, pairing automated in-device needle retraction with other safety products. The single-segment business depends on hospital purchasing channels, regulated manufacturing, Chinese suppliers, and a founder-held patent license.
Designs and sells VanishPoint retractable syringes, EasyPoint retractable needles and blood-collection products, plus IV safety catheters, tube holders, and catheter-hub products. Automated retraction occurs within the injection or collection device, aiming to reduce needlestick exposure and device reuse.
Generates recurring product revenue largely through U.S. general-line and specialty distributors, while serving international distributors and health-care customers directly. Manufacturing combines its Little Elm campus with Chinese contract manufacturers, even as selected production moves domestically in response to tariffs.
Operates as a founder-controlled single segment. Hospital group purchasing organizations and purchasing representatives shape market access; operations remain subject to device regulation, quality requirements, an open EasyPoint recall, government-backed capacity obligations, and founder-held patent licensing.
Company facts
Key statistics
Year to date −5.9% · Average volume (30d) 31.2K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026Q2 FY26 | — | $0.09 | — | — | $7.2M | — | +2.00% |
| May 15, 2026Q1 FY26 | — | −$0.14 | — | — | $7.2M | — | +4.69% |
| Mar 27, 2026Q4 FY25 | — | −$0.08 | — | — | $9.4M | — | +2.90% |
| Nov 14, 2025Q3 FY25 | — | $0.01 | — | — | $10.1M | — | +7.19% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $8.3M | $10.4M | $10.1M | $9.4M | $7.2M | $7.2M | |
| Gross profit | −$1.9K | −$107.1K | $1.7M | −$1.5M | $24.6K | $190.9K | |
| Operating income | −$4.7M | −$5.1M | −$3.7M | −$7.7M | −$6.2M | −$5.1M | |
| Net income | −$10.5M | −$87.5K | $371.0K | −$2.3M | −$4.2M | $2.8M | |
| Diluted EPS | −$0.35 | −$0.00 | $0.01 | −$0.08 | −$0.14 | $0.09 | |
| Gross margin | -0.0% | -1.0% | 16.7% | -16.2% | 0.3% | 2.7% | |
| Operating margin | -56.4% | -49.1% | -36.2% | -81.7% | -85.9% | -71.5% |
Fiscal years (4-quarter sums)FY24 $33.0M · FY25 $38.3M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $39.9M · Total debt $715.9K · Total assets $141.7M · Shareholders' equity $72.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 29.94M · Float 12.21M · 40.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Thomas J. Shaw | 16.48M | 55.00% | 13D | Aug 29, 2025 |
| Vanguard Capital Management LLC | 581.7K | 1.94% | 13F | Aug 13, 2026 |
| Eversept Partners, LP | 580.9K | 1.94% | 13F | Aug 14, 2026 |
| Renaissance Technologies LLC | 441.4K | 1.47% | 13F | Aug 13, 2026 |
| BlackRock, Inc. | 241.1K | 0.81% | 13F | Aug 7, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- BD
Broad safety syringe, safety needle, and blood-collection leader.
- Cardinal Health
Safety syringe and needle supplier with major U.S. channel reach.
- Embecta
Large insulin-syringe and safety-needle rival in diabetes injection.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Retractable Technologies | $0.7350 | +2.78% | $21.9M | — | — | 0.6 | −31.1% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Cardinal Health | $232.64 | −0.84% | $54.93B | 32.4 | 18.7 | 0.2 | +5.8% |
| Embecta | $5.01 | −0.79% | $299.6M | 3.4 | 3.1 | 0.3 | −8.1% |
| Median | 32.4 | 14.3 | 0.3 | −8.1% |